IceCure Medical Showcases Promising Cryoablation Results at CIRSE 2025 Annual Meeting
IceCure Medical Showcases Promising Cryoablation Results at CIRSE 2025 Annual Meeting
IceCure Medical Ltd. made headlines at the CIRSE 2025 Annual Meeting, held from September 13 to 17 in Barcelona, Spain. The company, known for its cutting-edge minimally invasive cryoablation technology, showcased its ProSense® system, designed to destroy tumors through freezing, offering patients a non-surgical alternative. The participation in this prestigious event illustrated the growing interest in this innovative treatment, particularly among interventional radiologists.
A Focus on Cryoablation and Significant Studies
One of the highlights of IceCure's presence at the conference was the presentation of significant clinical results from four independent studies. These studies focused on the efficacy of cryoablation for treating breast cancer and endometriosis, generating buzz among medical practitioners.
Dr. Eyal Shamir, the CEO of IceCure, noted, "Our participation at CIRSE this year was a tremendous success. ProSense® is paving the way as one of the most advanced LN2-based cryoablation systems for interventional radiologists aiming to expand their practices in breast care. We are grateful for the extensive research conducted by medical professionals who continue to support and share their positive experiences with ProSense® at such crucial conferences."
Among the presentations, Dr. Franco Orsi from the European Institute of Oncology delivered an honorary lecture titled "Breaking barriers in breast cancer - cryoablation as the ultimate expression of IO's de-escalation philosophy." His discussion emphasized how breast cancer therapy has evolved over time, moving away from radical surgeries towards more conservative approaches, with a focus on the PRECICE trial that exclusively used ProSense® for treating early-stage breast cancer in older patients.
Engaging Medical Professionals
IceCure's booth attracted numerous medical professionals eager to learn about the ProSense® system. Attendees could participate in live demonstrations and hands-on training sessions, which were highly praised. These opportunities allowed practitioners to further comprehend the advantages of using cryoablation technology, significantly enhancing patient care in oncology.
Independent Studies Highlighted at the Conference
The following studies presented at the conference emphasized the positive outcomes associated with ProSense®:
Cryoablation combined with Hormonal Therapy in Surgery-Ineligible Patients: This study by Dr. Sofia Baldi Giorgi indicated that the combination treatment significantly reduced tumor size compared to hormone therapy alone. The results suggested cryoablation could be a viable non-surgical option for patients deemed unsuitable for surgery, particularly elderly populations.
Cryoablation for Small Breast Cancers: Dr. Toulsie Ramthohul's prospective study highlighted the effectiveness of ProSense® in treating elderly patients with hormone receptor-positive breast cancers. The findings confirmed cryoablation's safety and efficiency as an alternative to surgery, a crucial consideration for older patients or those with unique health risks.
* Assessing Different Tumor Subtypes: Dr. Francesca Pugliese's research focused on evaluating the effectiveness of cryoablation in various breast tumor subtypes, solidifying its potential as a safe and effective treatment for low-grade hormone receptor-positive invasive ductal carcinoma.
Additionally, studies on treating endometriosis with ProSense® revealed substantial pain relief and positive treatment outcomes, emphasizing the system’s versatility for various conditions beyond oncology.
Looking Towards the Future
As IceCure Medical continues to innovate and improve treatment options with its ProSense® system, it plays a pivotal role in shaping the future techniques in interventional oncology. The positive clinical outcomes shared at CIRSE 2025 underline the potential benefits of adopting cryoablation in both breast cancer treatments and other medical scenarios.
The overall reception of IceCure's ProSense® technology at the CIRSE 2025 marks a significant milestone in the broader landscape of interventional radiology, setting the stage for future advancements in minimally invasive treatments that prioritize patient safety and comfort without compromising care.
In conclusion, IceCure Medical’s contributions to CIRSE 2025 have not only enhanced the visibility of its ProSense® system but have also highlighted the necessity for continued research and education among medical professionals in the fight against cancer and other debilitating conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.